Kiora Pharmaceuticals (KPRX) CDO uses 238 shares to cover tax withholding

Rhea-AI Filing Summary

Kiora Pharmaceuticals Chief Development Officer Eric Joseph Daniels reported a small tax-related share disposition. On March 3, 2026, he transferred 238 shares of common stock at $2.02 per share to satisfy tax withholding obligations. After this transaction, he directly held 26,137 common shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Daniels Eric Joseph

Role Chief Development Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	238	$2.02	$480.76

Holdings After Transaction: Common Stock — 26,137 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daniels Eric Joseph

(Last) (First) (Middle)

C/O KIORA PHARMACEUTICALS, INC.

169 SAXONY RD., SUITE 212

(Street)

ENCINITAS CA 92024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KIORA PHARMACEUTICALS INC [ KPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		F		238	D	$2.02	26,137	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Net Share settlement, shares withheld for employee tax obligation.

	/s/ Melissa Tosca, Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Kiora Pharmaceuticals (KPRX) report for Eric Joseph Daniels?

Kiora Pharmaceuticals reported that Chief Development Officer Eric Joseph Daniels disposed of 238 common shares on March 3, 2026. The disposition was a tax-withholding transaction, using shares to cover tax obligations rather than an open-market sale.

What does transaction code F mean in the KPRX Form 4 for Eric Joseph Daniels?

Transaction code F indicates a tax-withholding disposition, where shares are delivered to cover exercise price or tax liabilities. For Kiora Pharmaceuticals (KPRX), Eric Joseph Daniels used 238 shares this way, instead of selling them on the open market.

How many Kiora Pharmaceuticals (KPRX) shares does Eric Joseph Daniels hold after this Form 4?

After the reported tax-withholding transaction, Chief Development Officer Eric Joseph Daniels directly holds 26,137 shares of Kiora Pharmaceuticals common stock. This total reflects his position following the 238-share disposition on March 3, 2026.

Was the Kiora Pharmaceuticals (KPRX) insider transaction a market sale?

No, the transaction was a tax-withholding disposition, not a traditional market sale. Eric Joseph Daniels used 238 common shares of Kiora Pharmaceuticals to pay tax obligations, as indicated by transaction code F and the description in the filing.

At what price were the Kiora Pharmaceuticals (KPRX) shares valued in this Form 4 transaction?

The 238 Kiora Pharmaceuticals common shares used for tax withholding were valued at $2.02 per share. This price is the transaction value used in the Form 4 and reflects the amount applied toward Daniels’ tax liability on the date of disposition.